{"analyses":[{"ciLowerLimit":"0.844","ciPctValue":"95","ciUpperLimit":"1.078","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.448","paramType":"Hazard Ratio (HR)","paramValue":"0.954","statisticalComment":"Proportional Hazards model stratified by stage of disease and size of residual disease following initial staging surgery.","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.676","ciPctValue":"95","ciUpperLimit":"0.866","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.765","statisticalComment":"Proportional Hazards model stratified by stage of disease and size of residual disease following initial staging surgery.","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.2","upperLimit":"12.0","value":"11.0"},{"groupId":"OG001","lowerLimit":"11.4","upperLimit":"12.8","value":"12.3"},{"groupId":"OG002","lowerLimit":"14.2","upperLimit":"16.1","value":"15.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"625"},{"groupId":"OG001","value":"625"},{"groupId":"OG002","value":"623"}],"units":"Participants"}],"description":"Median progression-free survival (PFS). Onset of progression could be based on radiographic (RECIST) criteria or rising CA-125 (GCIG criteria).","dispersionType":"95% Confidence Interval","groups":[{"description":"Control therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus placebo (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received placebo every 3 weeks.","id":"OG000","title":"Arm I (Placebo, Paclitaxel, Carboplatin)"},{"description":"Bevacizumab-initiation therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus bevacizumab, 15 mg/kg (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received placebo every 3 weeks.","id":"OG001","title":"Arm II (Placebo, Paclitaxel, Carboplatin, Bevacizumab)"},{"description":"Bevacizumab-throughout therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus bevacizumab, 15 mg/kg (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received bevacizumab, 15 mg/kg every 3 weeks.","id":"OG002","title":"Arm III (Paclitaxel, Carboplatin, Bevacizumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From study entry until first disease progression, death or date of last contact, up to 6 years","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}